



EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

EMA/775576/2013

European Medicines Agency decision

P/0027/2014

of 24 January 2014

on the refusal of a paediatric investigation plan and on the granting of a waiver for diclofenac / levomenthol (EMEA-001536-PIP01-13) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

Disclaimer

This Decision does not constitute entitlement to the rewards and incentives referred to in Title V of Regulation (EC) No 1901/2006.

Only the English text is authentic.



European Medicines Agency decision

P/0027/2014

of 24 January 2014

on the refusal of a paediatric investigation plan and on the granting of a waiver for diclofenac / levomenthol (EMA-001536-PIP01-13) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

The European Medicines Agency,

Having regard to the Treaty on the Functioning of the European Union,

Having regard to Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use and amending Regulation (EEC) No. 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004¹,

Having regard to Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency²,

Having regard to the application submitted by GlaxoSmithKline Consumer Trading Services Limited on 30 August 2013 under Article 16(1) of Regulation (EC) No 1901/2006 also requesting a waiver under Article 13 of said Regulation,

Having regard to the opinion of the Paediatric Committee of the European Medicines Agency, issued on 6 December 2013, in accordance with Article 18 of Regulation (EC) No 1901/2006, and of its own motion in accordance with Article 12 of said Regulation,

Having regard to Article 25 of Regulation (EC) No 1901/2006,

Whereas:

- (1) The Paediatric Committee of the European Medicines Agency has given an opinion on the refusal of a paediatric investigation plan and on the granting of a waiver.
- (2) It is therefore appropriate to adopt a decision refusing a paediatric investigation plan.
- (3) It is therefore appropriate to adopt a decision granting a waiver.

¹ OJ L 378, 27.12.2006, p.1.

² OJ L 136, 30.4.2004, p. 1.

Has adopted this decision:

Article 1

A paediatric investigation plan for diclofenac / levomenthol, gel, cutaneous use, the details of which are set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby refused.

Article 2

A product-specific waiver for diclofenac / levomenthol, gel, cutaneous use, the details of which are set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby granted.

Article 3

This decision is addressed to GlaxoSmithKline Consumer Trading Services Limited, 980 Great West Road, TW8 9GS – Brentford, United Kingdom.

Done at London, 24 January 2014

For the European Medicines Agency
Guido Rasi
Executive Director
(Signature on file)

EMA/PDCO/698837/2013

Opinion of the Paediatric Committee on the refusal of a Paediatric Investigation Plan and on the granting of a product-specific waiver

EMA-001536-PIP01-13

Scope of the application

Active substance(s):

Diclofenac / Levomenthol

Condition(s):

Treatment of local pain and inflammation

Pharmaceutical form(s):

Gel

Route(s) of administration:

Cutaneous use

Name / corporate name of the PIP applicant:

GlaxoSmithKline Consumer Trading Services Limited

Basis for opinion

Pursuant to Article 16(1) of Regulation (EC) No 1901/2006 as amended, GlaxoSmithKline Consumer Trading Services Limited submitted for agreement to the European Medicines Agency on 30 August 2013 an application for a paediatric investigation plan for the above mentioned medicinal product and a waiver under Article 13 of said Regulation.

The procedure started on 10 October 2013.

Opinion

1. The Paediatric Committee, having assessed the proposed paediatric investigation plan in accordance with Article 17 of Regulation (EC) No 1901/2006 as amended, recommends as set out in the appended summary report:

- to refuse the paediatric investigation plan in accordance with Article 18 of said Regulation as the measures and the timelines are not appropriate to ensure the generation of the necessary data determining the conditions in which the medicinal product may be used to treat the paediatric population or some subsets, nor to adapt a paediatric formulation, or do not bring expected significant therapeutic benefit;
- to grant a product-specific waiver for all subsets of the paediatric population on its own motion in accordance with Article 12 of said Regulation and concluded in accordance with Article 11(1)(c) of said Regulation, on the grounds that the specific medicinal product does not represent a significant therapeutic benefit over existing treatments for paediatric patients.

The Icelandic and the Norwegian Paediatric Committee members agree with the above-mentioned recommendation of the Paediatric Committee.

2. The grounds for the granting of the waiver are set out in Annex I.

This opinion is forwarded to the applicant and the Executive Director of the European Medicines Agency, together with its annex and appendix.

London, 6 December 2013

On behalf of the Paediatric Committee
Dr Dirk Mentzer, Chairman
(Signature on file)

Annex I

Grounds for the granting of the waiver

1. Waiver

1.1. Condition: treatment of local pain and inflammation

The waiver applies to:

- All subsets of the paediatric population from birth to less than 18 years of age;
- for gel for cutaneous use;
- on the grounds that the specific medicinal product does not represent a significant therapeutic benefit over existing treatments.